Vericel (NASDAQ: VCEL ) has created a niche in regenerative medicine that the market undervalues. Whereas most investors look at big biotech names chasing blockbuster drug approvals, Vericel has steadily grown its revenue base with FDA-approved, revenue-generating products like MACI, Epicel, and NexoBrid. TheI have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologies and for ...